These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Kunzelmann K; Mall M Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996 [TBL] [Abstract][Full Text] [Related]
15. Sinupret activates CFTR and TMEM16A-dependent transepithelial chloride transport and improves indicators of mucociliary clearance. Zhang S; Skinner D; Hicks SB; Bevensee MO; Sorscher EJ; Lazrak A; Matalon S; McNicholas CM; Woodworth BA PLoS One; 2014; 9(8):e104090. PubMed ID: 25117505 [TBL] [Abstract][Full Text] [Related]
16. TMEM16A (ANO1) as a therapeutic target in cystic fibrosis. Galietta LJV Curr Opin Pharmacol; 2022 Jun; 64():102206. PubMed ID: 35364521 [TBL] [Abstract][Full Text] [Related]
17. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. Myerburg MM; King JD; Oyster NM; Fitch AC; Magill A; Baty CJ; Watkins SC; Kolls JK; Pilewski JM; Hallows KR Am J Respir Cell Mol Biol; 2010 Jun; 42(6):676-84. PubMed ID: 19617399 [TBL] [Abstract][Full Text] [Related]